Immunosuppressive tocilizumab prevents astrocyte induced neurotoxicity in hiPSC-LRRK2 Parkinson's disease by targeting receptor interleukin-6
Meritxell Pons‐Espinal, Lucas Blasco-Agell, Irene Fernández‐Carasa, Pol Andrés‐Benito, Angelique di Domenico, Yvonne Richaud‐Patín, Valentina Baruffi, Laura Marruecos, Lluı́s Espinosa, Alícia Garrido, EDUARDO S. TOLOSA, Michael J. Edel, Manel Juan, José Luis Mosquera, Isidró Ferrer, , Antonella Consiglio
The paper shows that tocilizumab, an IL-6 receptor inhibitor, prevents astrocyte-induced neurotoxicity in Parkinson's disease by blocking IL-6 signaling in neurons.
JCI Insight · Feb 8, 2024Peer-reviewedNeuroscience